ResearcherWuhan Union HospitalActive in the last 2 years

Jun Xue

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7323-0331; OpenAlex author ID A5054081137. Sources: OpenAlex.

Their work

Papers: 3 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 12

Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 3

Neoadjuvant Early Stereotactic Body Radiation Therapy Followed by Chemoimmunotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. Last author DOI 10.1016/j.adro.2026.102128 ↗
Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study. Co-author DOI 10.1093/oncolo/oyae171 ↗
Utility of Dark-Blood Dual-Energy CT Images for Predicting Vascular Involvement and R0 Resection in Patients With Pancreatic Cancer. Co-author DOI 10.2214/ajr.22.28640 ↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Shuhan Zhao · 1 shared paper, 2026 · strength 0.26
- Paper Neoadjuvant Early Stereotactic Body Radiation Therapy Followed by Chemoimmunotherapy in Borderline Resectable and Local… DOI 10.1016/j.adro.2026.102128 ↗
Tao Yin · 1 shared paper, 2026 · strength 0.26
- Paper Neoadjuvant Early Stereotactic Body Radiation Therapy Followed by Chemoimmunotherapy in Borderline Resectable and Local… DOI 10.1016/j.adro.2026.102128 ↗
Shanmiao Gou · 1 shared paper, 2026 · strength 0.26
- Paper Neoadjuvant Early Stereotactic Body Radiation Therapy Followed by Chemoimmunotherapy in Borderline Resectable and Local… DOI 10.1016/j.adro.2026.102128 ↗
Tao Zhang · 1 shared paper, 2024 · strength 0.19
- Paper Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicent… DOI 10.1093/oncolo/oyae171 ↗
Min Jin · 1 shared paper, 2024 · strength 0.19
- Paper Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicent… DOI 10.1093/oncolo/oyae171 ↗
Zhenyu Lin · 1 shared paper, 2024 · strength 0.19
- Paper Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicent… DOI 10.1093/oncolo/oyae171 ↗
Hongli Liu · 1 shared paper, 2024 · strength 0.19
- Paper Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicent… DOI 10.1093/oncolo/oyae171 ↗
Jianli Hu · 1 shared paper, 2024 · strength 0.19
- Paper Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicent… DOI 10.1093/oncolo/oyae171 ↗
Keke Si · 1 shared paper, 2023 · strength 0.18
- Paper Utility of Dark-Blood Dual-Energy CT Images for Predicting Vascular Involvement and R0 Resection in Patients With Pancr… DOI 10.2214/ajr.22.28640 ↗
Xin Li · 1 shared paper, 2023 · strength 0.18
- Paper Utility of Dark-Blood Dual-Energy CT Images for Predicting Vascular Involvement and R0 Resection in Patients With Pancr… DOI 10.2214/ajr.22.28640 ↗
Ping Han · 1 shared paper, 2023 · strength 0.18
- Paper Utility of Dark-Blood Dual-Energy CT Images for Predicting Vascular Involvement and R0 Resection in Patients With Pancr… DOI 10.2214/ajr.22.28640 ↗
Heshui Wu · 1 shared paper, 2023 · strength 0.18
- Paper Utility of Dark-Blood Dual-Energy CT Images for Predicting Vascular Involvement and R0 Resection in Patients With Pancr… DOI 10.2214/ajr.22.28640 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.